Correlates of immune protection following cutaneous immunization with an attenuated Burkholderia pseudomallei vaccine

Infection and Immunity

Volumn 81, Issue 12, 2013, Pages 4626-4634

  Silva, Ediane B ^a   Goodyear, Andrew ^a   Sutherland, Marjorie D ^a   Podnecky, Nicole L ^a   Gonzalez Juarrero, Mercedes ^a   Schweizer, Herbert P ^a   Dow, Steven W ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; BACTERIAL VACCINE; BURKHOLDERIA PSEUDOMALLEI VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; LIVE VACCINE; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BACTERIAL LOAD; BACTERIAL VIRULENCE; BURKHOLDERIA PSEUDOMALLEI; CD8+ T LYMPHOCYTE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DENDRITIC CELL; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; FEMALE; GENE DELETION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; LIVER PARENCHYMA; LUNG PARENCHYMA; MELIOIDOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN TISSUE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CD4+ T LYMPHOCYTE; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; MICROBIOLOGY; NEUTROPHIL; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; BURKHOLDERIA PSEUDOMALLEI; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; IMMUNITY, HUMORAL; IMMUNIZATION; MELIOIDOSIS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTROPHILS; VACCINATION; VACCINES, ATTENUATED;

EID: 84891708656     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00915-13     Document Type: Article

References (61)

1. Cheng AC, Currie BJ. 2005. Melioidosis: epidemiology, pathophysiology, and management. Clin. Microbiol. Rev. 18:383-416
2. Wiersinga WJ, van der Poll T, White NJ, Day NP, Peacock SJ. 2006. Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat. Rev. Microbiol. 4:272-282
3. Wiersinga WJ, Currie BJ, Peacock SJ. 2012. Melioidosis. N. Engl. J. Med. 367:1035-1044
4. Dance DAB. 2000. Melioidosis as an emerging global problem. Acta Trop. 74:115-119
5. Dance DA. 1991. Melioidosis: the tip of the iceberg? Clin. Microbiol. Rev. 4:52-60
6. Currie BJ, Dance DA, Cheng AC. 2008. The global distribution of Burkholderia pseudomallei and melioidosis: an update. Trans. R. Soc. Trop. Med. Hyg. 102(Suppl 1):S1-S4
7. Batchelor BI, Paul J, Trakulsomboon S, Mgongo M, Dance DA. 1994. Melioidosis survey in Kenya. Trans. R. Soc. Trop. Med. Hyg. 88:181
8. Yabuuchi E, Arakawa M. 1993. Burkholderia pseudomallei and melioidosis: be aware in temperate area. Microbiol. Immunol. 37:823-836
9. Wiersinga WJ, van der Poll T. 2009. Burkholderia pseudomallei tropism and the melioidosis road map. J. Infect. Dis. 199:1720-1722
10. Barnes JL, Ketheesan N. 2005. Route of infection in melioidosis. Emerg. Infect. Dis. 11:638-639
11. White NJ. 2003. Melioidosis. Lancet 361:1715-1722
12. Tiangpitayakorn C, Songsivilai S, Piyasangthong N, Dharakul T. 1997. Speed of detection of Burkholderia pseudomallei in blood cultures and its correlation with the clinical outcome. Am. J. Trop. Med. Hyg. 57:96-99
13. Chaowagul W, White NJ, Dance DA, Wattanagoon Y, Naigowit P, Davis TM, Looareesuwan S, Pitakwatchara N. 1989. Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand. J. Infect. Dis. 159:890-899
14. Rode JW, Webling DD. 1981. Melioidosis in the Northern Territory of Australia. Med. J. Aust. 1:181-184
15. Thin RN, Brown M, Stewart JB, Garrett CJ. 1970. Melioidosis: a report of ten cases. Q. J. Med. 39:115-127
16. Ngauy V, Lemeshev Y, Sadkowski L, Crawford G. 2005. Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. J. Clin. Microbiol. 43:970-972
17. Vatcharapreechasakul T, Suputtamongkol Y, Dance DA, Chaowagul W, White NJ. 1992. Pseudomonas pseudomallei liver abscesses: a clinical, laboratory, and ultrasonographic study. Clin. Infect. Dis. 14:412-417
18. Wong KT, Puthucheary SD, Vadivelu J. 1995. The histopathology of human melioidosis. Histopathology 26:51-55
19. Schweizer HP. 2012. Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis. Future Microbiol. 7:1389-1399
20. Rholl DA, Papp-Wallace KM, Tomaras AP, Vasil ML, Bonomo RA, Schweizer HP. 2011. Molecular investigations of PenA-mediated betalactam resistance in Burkholderia pseudomallei. Front. Microbiol. 2:139. doi:10.3389/fmicb.2011.00139
21. Mima T, Schweizer HP. 2010. The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. Antimicrob. Agents Chemother. 54:3113-3120
22. Moore RA, DeShazer D, Reckseidler S, Weissman A, Woods DE. 1999. Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei. Antimicrob. Agents Chemother. 43:465-470
23. Trunck LA, Propst KL, Wuthiekanun V, Tuanyok A, Beckstrom-Sternberg SM, Beckstrom-Sternberg JS, Peacock SJ, Keim P, Dow SW, Schweizer HP. 2009. Molecular basis of rare aminoglycoside susceptibility and pathogenesis of Burkholderia pseudomallei clinical isolates from Thailand. PLoS Negl. Trop. Dis. 3:e519. doi:10.1371/journal.pntd.0000519
24. Carruthers MM. 1981. Recrudescent melioidosis mimicking lung abscess. Am. Rev. Respir. Dis. 124:756-758
25. Chan CK, Hyland RH, Leers WD, Hutcheon MA, Chang D. 1984. Pleuropulmonary melioidosis in a Cambodian refugee. Can. Med. Assoc. J. 131:1365-1367
26. Pit S, Chea FK, Jamal F. 1988. Melioidosis with brain abscess. Postgrad. Med. J. 64:140-142
27. Wilson JW, Ashdown LR, Richards MJ, Sutherland AD, Cade JF. 1987. Subacute pulmonary melioidosis in a temperate climate. Med. J. Aust. 147:95-96
28. Silva EB, Dow SW. 2013. Development of Burkholderia mallei and pseudomallei vaccines. Front. Cell. Infect. Microbiol. 3:10. doi:10.3389/fcimb.2013.00010
29. Atkins T, Prior R, Mack K, Russell P, Nelson M, Prior J, Ellis J, Oyston PC, Dougan G, Titball RW. 2002. Characterisation of an acapsular mutant of Burkholderia pseudomallei identified by signature tagged mutagenesis. J. Med. Microbiol. 51:539-547
30. Haque A, Chu K, Easton A, Stevens MP, Galyov EE, Atkins T, Titball R, Bancroft GJ. 2006. A live experimental vaccine against Burkholderia pseudomallei elicits CD4+T cell-mediated immunity, priming T cells specific for 2 type III secretion system proteins. J. Infect. Dis. 194:1241-1248
31. Rodrigues F, Sarkar-Tyson M, Harding SV, Sim SH, Chua HH, Lin CH, Han X, Karuturi RK, Sung K, Yu K, Chen W, Atkins TP, Titball RW, Tan P. 2006. Global map of growth-regulated gene expression in Burkholderia pseudomallei, the causative agent of melioidosis. J. Bacteriol. 188: 8178-8188
32. Cuccui J, Easton A, Chu KK, Bancroft GJ, Oyston PC, Titball RW, Wren BW. 2007. Development of signature-tagged mutagenesis in Burkholderia pseudomallei to identify genes important in survival and pathogenesis. Infect. Immun. 75:1186-1195
33. Breitbach K, Kohler J, Steinmetz I. 2008. Induction of protective immunity against Burkholderia pseudomallei using attenuated mutants with defects in the intracellular life cycle. Trans. R. Soc. Trop. Med. Hyg. 102(Suppl 1):S89-S94
34. Stevens MP, Haque A, Atkins T, Hill J, Wood MW, Easton A, Nelson M, Underwood-Fowler C, Titball RW, Bancroft GJ, Galyov EE. 2004. Attenuated virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion mutant in murine models of melioidosis. Microbiology 150:2669-2676
35. Srilunchang T, Proungvitaya T, Wongratanacheewin S, Strugnell R, Homchampa P. 2009. Construction and characterization of an unmarked aroC deletion mutant of Burkholderia pseudomallei strain A2. Southeast Asian J. Trop. Med. Public Health 40:123-130
36. Druar C, Yu F, Barnes JL, Okinaka RT, Chantratita N, Beg S, Stratilo CW, Olive AJ, Soltes G, Russell ML, Limmathurotsakul D, Norton RE, Ni SX, Picking WD, Jackson PJ, Stewart DI, Tsvetnitsky V, Picking WL, Cherwonogrodzky JW, Ketheesan N, Peacock SJ, Wiersma EJ. 2008. Evaluating Burkholderia pseudomallei Bip proteins as vaccines and Bip antibodies as detection agents. FEMS Immunol. Med. Microbiol. 52:78-87
37. Burtnick MN, Brett PJ, Harding SV, Ngugi SA, Ribot WJ, Chantratita N, Scorpio A, Milne TS, Dean RE, Fritz DL, Peacock SJ, Prior JL, Atkins TP, Deshazer D. 2011. The cluster 1 type VI secretion system is a major virulence determinant in Burkholderia pseudomallei. Infect. Immun. 79: 1512-1525
38. Nelson M, Prior JL, Lever MS, Jones HE, Atkins TP, Titball RW. 2004. Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. J. Med. Microbiol. 53:1177-1182
39. Brett PJ, Mah DC, Woods DE. 1994. Isolation and characterization of Pseudomonas pseudomallei flagellin proteins. Infect. Immun. 62:1914-1919
40. Harland DN, Chu K, Haque A, Nelson M, Walker NJ, Sarkar-Tyson M, Atkins TP, Moore B, Brown KA, Bancroft G, Titball RW, Atkins HS. 2007 Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis. Infect. Immun. 75:4173-4180
41. Nieves W, Asakrah S, Qazi O, Brown KA, Kurtz J, Aucoin DP, McLachlan JB, Roy CJ, Morici LA. 2011. A naturally derived outermembrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection. Vaccine 29:8381-8389
42. Su YC, Wan KL, Mohamed R, Nathan S. 2010. Immunization with the recombinant Burkholderia pseudomallei outer membrane protein Omp85 induces protective immunity in mice. Vaccine 28:5005-5011
43. Atkins T, Prior RG, Mack K, Russell P, Nelson M, Oyston PC, Dougan G, Titball RW. 2002. A mutant of Burkholderia pseudomallei, auxotrophic in the branched chain amino acid biosynthetic pathway, is attenuated and protective in a murine model of melioidosis. Infect. Immun. 70:5290-5294
44. Propst KL, Mima T, Choi KH, Dow SW, Schweizer HP. 2010. A Burkholderia pseudomallei deltapurM mutant is avirulent in immunocompetent and immunodeficient animals: candidate strain for exclusion from select-agent lists. Infect. Immun. 78:3136-3143
45. DeShazer D, Brett PJ, Carlyon R, Woods DE. 1997. Mutagenesis of Burkholderia pseudomallei with Tn5-OT182: isolation of motility mutants and molecular characterization of the flagellin structural gene. J. Bacteriol. 179:2116-2125
46. Hayden HS, Lim R, Brittnacher MJ, Sims EH, Ramage ER, Fong C, Wu Z, Crist E, Chang J, Zhou Y, Radey M, Rohmer L, Haugen E, Gillett W, Wuthiekanun V, Peacock SJ, Kaul R, Miller SI, Manoil C, Jacobs MA. 2012 Evolution of Burkholderia pseudomallei in recurrent melioidosis. PLoS One 7:e36507. doi:10.1371/journal.pone.0036507
47. Frey A, Di Canzio J, Zurakowski D. 1998. A statistically defined endpoint titer determination method for immunoassays. J. Immunol. Methods 221: 35-41
48. Sutherland MD, Goodyear AW, Troyer RM, Chandler JC, Dow SW, Belisle JT. 2012. Post-exposure immunization against Francisella tularensis membrane proteins augments protective efficacy of gentamicin in a mouse model of pneumonic tularemia. Vaccine 30:4977-4982
49. Choi KH, Mima T, Casart Y, Rholl D, Kumar A, Beacham IR, Schweizer HP. 2008. Genetic tools for select-agent-compliant manipulation of Burkholderia pseudomallei. Appl. Environ. Microbiol. 74:1064-1075
50. Mitchell LA, Hansen RJ, Beaupre AJ, Gustafson DL, Dow SW. 2013. Optimized dosing of a CCR2 antagonist for amplification of vaccine immunity. Int. Immunopharmacol. 15:357-363
51. Bosio CM, Goodyear AW, Dow SW. 2005. Early interaction of Yersinia pestis with APCs in the lung. J. Immunol. 175:6750-6756
52. Liu B, Koo GC, Yap EH, Chua KL, Gan YH. 2002. Model of differential susceptibility to mucosal Burkholderia pseudomallei infection. Infect. Immun. 70:504-511
53. Bottex C, Gauthier YP, Hagen RM, Finke EJ, Splettstosser WD, Thibault FM, Neubauer H, Vidal DR. 2005. Attempted passive prophylaxis with a monoclonal anti-Burkholderia pseudomallei exopolysaccharide antibody in a murine model of melioidosis. Immunopharmacol. Immunotoxicol. 27:565-583
54. Bryan LE, Wong S, Woods DE, Dance DA, Chaowagul W. 1994. Passive protection of diabetic rats with antisera specific for the polysaccharide portion of the lipopolysaccharide isolated from Pseudomonas pseudomallei. Can. J. Infect. Dis. 5:170-178
55. Jones SM, Ellis JF, Russell P, Griffin KF, Oyston PC. 2002. Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins. J. Med. Microbiol. 51:1055-1062
56. Mitchell LA, Henderson AJ, Dow SW. 2012. Suppression of vaccine immunity by inflammatory monocytes. J. Immunol. 189:5612-5621
57. Lazar Adler NR, Govan B, Cullinane M, Harper M, Adler B, Boyce JD. 2009 The molecular and cellular basis of pathogenesis in melioidosis: how does Burkholderia pseudomallei cause disease? FEMS Microbiol. Rev. 33: 1079-1099
58. Nash AA, Jayasuriya A, Phelan J, Cobbold SP, Waldmann H, Prospero T. 1987. Different roles for L3T4 + and Lyt 2 + T cell subsets in the control of an acute herpes simplex virus infection of the skin and nervous system. J. Gen. Virol. 68:825-833
59. Ho M, Schollaardt T, Smith MD, Perry MB, Brett PJ, Chaowagul W, Bryan LE. 1997. Specificity and functional activity of anti-Burkholderia pseudomallei polysaccharide antibodies. Infect. Immun. 65:3648-3653
60. Zhang S, Feng SH, Li B, Kim HY, Rodriguez J, Tsai S, Lo SC. 2011. In vitro and in vivo studies of monoclonal antibodies with prominent bactericidal activity against Burkholderia pseudomallei and Burkholderia mallei. Clin. Vaccine Immunol. 18:825-834
61. Abadie V, Badell E, Douillard P, Ensergueix D, Leenen PJ, Tanguy M, Fiette L, Saeland S, Gicquel B, Winter N. 2005. Neutrophils rapidly migrate via lymphatics after Mycobacterium bovis BCG intradermal vaccination and shuttle live bacilli to the draining lymph nodes. Blood 106: 1843-1850